University corner: Touchstone Innovations
Last month, Touchstone Innovations – the commercialisation firm spun out of Imperial College London – participated in a £60m ($73m) series C round launched by Cell Medica, a cellular immunotherapy developer that Touchstone co-founded in 2007.
A $73m series C round may not be record-breaking, but in the spinout world, where sums tend to be significantly lower on average, that is a notable sum. And there is no question that immunotherapy, a treatment that harnesses the body’s own immune system…
